Dr. Jackson Brougher, co-founder and Chief Scientific Officer at Doloromics, embarked on his notable journey in the field of neuroscience with his PhD studies at The University of Texas at Dallas, where he specialized in Systems Neuroscience. During his PhD, Brougher's research centered on Vagus Nerve Stimulation (VNS), dopaminergic signaling pathways, and pharmacological interventions, with a keen focus on understanding the impact of neuromodulator signaling on motor map plasticity​​. This foundational work laid the groundwork for his transition into a pioneering role in pain therapeutics. At Doloromics, Brougher has been instrumental in leveraging his research to address the complex challenges of chronic pain treatment. As the architect and strategist behind the DOLOReS platform, he has spearheaded efforts in early target discovery and validation, focusing on the development of novel drug targets that aim to treat chronic pain without reliance on opioids. His work is characterized by a deep dive into the human transcriptome, aiming to unravel the mechanisms behind pain perception and sensitization in sensory neurons, thereby identifying potential drug therapies focused on individual types of sensory neurons.